98%
921
2 minutes
20
Background: Fospropofol, a water-soluble prodrug of propofol, is metabolized into propofol by alkaline phosphatase after administration. This study aimed to develop a pharmacokinetic-pharmacodynamic (PK-PD) model that correlates the propofol concentration in exhaled air (Ce-pro-f) with its anesthetic effects, as measured by the bispectral index (BIS) in beagles.
Methods: Beagles receiving a single intravenous infusion of fospropofol at varying doses were divided into three groups (n = 6): the DBL-fospro group (15 mg/kg), the DBM-fospro group (30 mg/kg), and the DBH-fospro group (60 mg/kg). Propofol levels were monitored using VUV-TOF MS from pre-administration to recovery. Correlations between Ce-pro-f and blood concentration (C-pro), as well as between Ce-pro-f and the BIS were investigated. PK, PD, and PK-PD models describing the relationship between Ce and BIS were also analyzed.
Results: Propofol concentration in exhaled air can be quantified using VUV-TOF MS at a mass-to-charge ratio of 177.6. After fospropofol injection, the peak Ce-pro-f was delayed compared to C-pro. The PK model of Ce-pro-f can be described using a noncompartmental approach, corresponding to the linear PK characteristics. Additionally, Ce-pro-f showed a moderate to strong negative correlation with BIS values. In the PK-PD model, the PK component was well characterized by a two-compartment model incorporating a first-order delay to account for the time lag of Ce-pro-f relative to C-pro. The PD component was well fitted by the inhibitory sigmoid E model, with an indirect connection model selected to explain the observed lag between BIS signals and Ce-pro-f peaks.
Conclusions: This study is the first to develop a PK-PD model for exhaled propofol in beagles after fospropofol disodium administration. The PK profile was described by a two-compartment model with a first-order delay, and the PD profile was modeled using an inhibitory sigmoid E model with an indirect connection model to capture the lag between BIS and exhaled propofol peaks.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869703 | PMC |
http://dx.doi.org/10.1186/s12917-025-04570-w | DOI Listing |
Int J Antimicrob Agents
September 2025
Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China; National Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, China. Electronic address:
Background: This study characterized the urinary pharmacokinetics and pharmacodynamics (PK/PD) of linezolid (LNZ) in critically ill patients with renal impairment and nosocomial multidrug-resistant Gram-positive urinary tract infections (UTIs). The aim was to address therapeutic challenges arising from limited treatment options and uncertain urinary excretion, to establish optimized dosing strategies.
Methods: A prospective observational study was conducted in ICU patients with renal impairment.
Mol Pharm
September 2025
Johnson & Johnson, Translational PK/PD & Investigational Toxicology, Spring House, Pennsylvania 19002, United States.
Human intestinal permeability is a key determinant of the oral fraction absorbed () of active pharmaceutical ingredients (APIs). This study evaluated the ability of an in-house canine Mdr1 (cMdr1) knockout (KO) Madin-Darby Canine Kidney (MDCK) cell line to correlate apparent permeability () with human small intestinal permeability (). values of 16 reference compounds with high, medium, or low permeabilities were measured in the in-house cMdr1 KO MDCK protocol under pH gradient (6.
View Article and Find Full Text PDFJ Clin Pharmacol
September 2025
Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, CA, USA.
Oncolytic viruses are an emerging class of immunotherapies for cancer treatment. Talimogene laherparepvec (T-VEC) is a first-in-class oncolytic virus approved globally for advanced melanoma. Herein, we describe the quantitative clinical pharmacology aspects of T-VEC that supported the development of this unique therapy.
View Article and Find Full Text PDFToxicon
September 2025
Research and Innovation Hub, Innovation Aesthetics, London, UK.
Botulinum Neurotoxin Type A (BoNT-A) remains the cornerstone of glabellar frown line treatment, yet conventional low-dose, high-volume protocols often result in limited durability and imprecise diffusion. This study presents multiscale, in silico framework specifically designed to evaluate high-dose (60-80 Units), low-volume (≤0.045 mL/site) BoNT-A glabellar injection strategies across anatomically realistic conditions.
View Article and Find Full Text PDFClin Transl Sci
September 2025
Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
The objective of this study was to develop a population pharmacokinetic model for linezolid in hematooncological patients with sepsis, and to propose dosing optimization based on pharmacokinetic covariates that would lead to improved achievement of the PK/PD target. Therapeutic drug monitoring data from hematooncological patients treated with linezolid for suspected or proven sepsis were analyzed. A pharmacokinetic population model for linezolid was constructed using a nonlinear mixed-effects modeling approach.
View Article and Find Full Text PDF